/ /

  • linkedin
  • Increase Font
  • Sharebar

    Corneal inlays still altering landscape of presbyopia

    Las Vegas—The prospect of an expanding armamentarium of corneal inlays for presbyopia correction is an exciting development, said Jay A. Pepose, MD, PhD.

    Presbyopia is the most common universal ocular condition, affecting about 2 billion people worldwide and more than 80 million people in the United States between the ages 45 and 64, said Dr. Pepose at Refractive Surgery 2015.

    Dr. Pepose provided an overview of four corneal inlays:

    • One is currently FDA approved (Kamra, AcuFocus);
    • Two are undergoing FDA review (Raindrop, Revision Optics; Flexivue Microlens, Presbia); and
    • One is in early stages of clinical development (Icolens, Neoptics).

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results